425: Waters Details BD SpinCo Acquisition, Outlook at JPM Conf

Waters Corporation presented at the J.P. Morgan Healthcare Conference, detailing its proposed acquisition of Augusta SpinCo Corporation from Becton, Dickinson and Company and outlining its strategic and financial outlook.

Summary

• Waters Corporation presented at the J.P. Morgan Healthcare Conference on January 12, 2026, providing high-level commentary on its business performance and strategic direction.
• The presentation highlighted the proposed transaction where Waters will acquire Augusta SpinCo Corporation (SpinCo) from Becton, Dickinson and Company (BD).
• The transaction is expected to double Waters' Total Addressable Market (TAM) to $40 billion in attractive, growth-accretive markets.
• Waters anticipates significant value creation from the acquisition, including substantial cost and revenue synergies.
• The company outlined its 'Executing from a Position of Strength' with a simple and repeatable business model, serving attractive, volume-driven markets.
• Waters has successfully executed a bold transformation plan since 2020, regaining commercial momentum, entering faster-growth adjacencies, and delivering pioneering innovation.
• The company projects industry-leading financial outlook with strong revenue growth, EBIT margin expansion, and EPS growth from CY 2025E-2030E.

Sentiment

Score: 9

Explanation: The filing is an investor presentation for a major healthcare conference, primarily focused on a significant strategic acquisition and a very positive outlook for the combined entity. It highlights strong current performance, substantial synergy potential, and projected industry-leading financial metrics, indicating a highly optimistic and growth-oriented sentiment.

Positives

• Waters has a 'Simple & Repeatable Business Model' with a high-quality, wide-moat business in volume-driven, recurring, regulated settings.
• The company serves attractive, volume-driven markets with a $19 billion TAM ($12B Core + $7B Higher Growth Adjacencies).
• Waters has successfully executed a transformation plan since 2020, regaining commercial momentum and delivering pioneering innovation.
• Key Commercial Execution KPIs are running ahead, including +270% YTD sales growth for Waters Alliance iS, +40% for Waters Xevo TQ Absolute, and +35% for Waters MaxPeak chemistry sales (all constant currency for first 9 months of 2025 vs. 2024).
• Successfully entered high-growth adjacencies, with idiosyncratic growth drivers exceeding targets, contributing +95bps from Bioseparations, +70bps from Bioanalytical Characterization, and +95bps from LC-MS into Dx to 2025E growth.
• Anticipates $30M in 2025E from India (including GLP-1s), $20M from GLP-1s, and $30M from PFAS.
• Exhibits a 'Best-in-Class Financial Profile' with $3.1B Total Revenue (TTM), 59.0% Gross Margin (TTM), 30.4% Adj. Operating Margin (TTM), and 24% Free Cash Flow as % of Sales (TTM) as of September 27, 2025.
• The proposed acquisition of BD Biosciences & Diagnostic Solutions is expected to double Waters' TAM to $40 billion.
• The acquired business has a well-established portfolio with $3.3B Total GAAP Revenue (FY-25) and >80% recurring revenue.
• Significant value creation opportunity from the acquisition, including estimated cost synergies of $200M by year 3 and revenue synergies of $290M by year 5.
• The combined company is projected to have industry-leading financial outlook with higher revenue growth CAGR, Adj. EBIT Margin Expansion, and Adj. EPS Growth compared to peers from CY 2025E-30E.

Risks

• One or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions.
• The required approval by Waters' stockholders may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the transaction or integrating the businesses of Waters and SpinCo.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes.
• Changes in general political, economic, regulatory, environmental, trade, and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies.
• The risk that the anticipated tax treatment of the proposed transaction is not obtained.
• Risk of greater than expected difficulty in separating the business of SpinCo from BD.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties.
• The credit ratings of the combined company may decline following the proposed transaction.
• The announcement or consummation of the proposed transaction may have a negative effect on the market price of Waters and BD capital stock or on their operating results.

Future Outlook

Waters expects continued strong instrument replacement dynamics and 200bps+ annual core growth contribution from 2026-2030, driven by biologics, informatics (subscription model transition), GLP-1s, PFAS, and generics (India ex-GLP-1s). The proposed acquisition of BD Biosciences & Diagnostic Solutions is anticipated to accelerate high-growth adjacencies, provide commercial scale execution uplift, and leverage Waters' focus and discipline, leading to industry-leading financial performance with higher revenue growth, EBIT margin expansion, and EPS growth compared to peers from CY 2025E-2030E.

Management Comments

• Executing from a Position of Strength
• Significant Value Creation Opportunity Ahead
• Industry-Leading Financial Outlook
• Successfully Executed Bold Transformation Plan Since 2020
• Delivering Strong Commercial Execution & Revitalized Innovation
• Built New Vectors of Core Growth Accretion
• Resulting in Industry-Leading Financials
• Expect More of the Same in 2026
• Transaction Doubles Waters TAM to $40B in Attractive, Growth-Accretive Markets

Industry Context

The acquisition of BD Biosciences & Diagnostic Solutions positions Waters to expand significantly into high-growth adjacencies like clinical flow cytometry, single-cell multiomics, microbiology, and molecular diagnostics. This move leverages Waters' existing strengths in chromatography and mass spectrometry, particularly its $265M LC-MS clinical business, by adding BD's established channel, service, automation, and regulatory capabilities. The transaction is framed as a strategic move to double Waters' total addressable market and enhance its leadership in regulated, high-volume applications, aligning with broader trends of convergence between chemistry and biology in life sciences and diagnostics.

Comparison to Industry Standards

• Waters has the highest service satisfaction score among all instrument vendors, according to SDi 2024 Analytical & Life Science Instrumentation Service Market (2021-2024 End User Perspectives).
• Waters' 2024 tNPS score is over 20 points higher than the TSIA benchmark average.
• Approximately 80% of drugs filed with the FDA, EMA, and China NMPA in 2023 were done using Waters' Empower software, indicating a dominant position in regulated environments.
• Waters' financial profile (Gross Margin, Adj. Operating Margin, FCF as % of Sales) is presented as 'Best-in-Class' compared to unnamed peers in the Life Science Tools (LST) industry.
• The combined company (Waters + BD Biosciences & Diagnostic Solutions) is projected to achieve higher Revenue Growth CAGR, Adj. EBIT Margin Expansion, and Adj. EPS Growth (CY 2025E-30E) compared to a peer average based on Bloomberg consensus analysis as of January 6, 2026.
• The estimated cost synergies of $200M (~5% of cost base) are compared favorably to the EMD Millipore + Sigma Aldrich acquisition, which achieved ~8% of cost base, suggesting a conservative or achievable target.

Stakeholder Impact

• Shareholders: Potential for significant value creation from the acquisition, including synergies and expanded market opportunities. Risk of litigation, negative impact on stock price if the transaction is not successful or delayed.
• Employees: Risk of inability to retain and hire key personnel in the combined company. Potential for disruption of management time.
• Customers: Potential for enhanced product offerings and service capabilities from the combined entity. Risk of disruption to business, contractual, and operational relationships during the transaction.
• Suppliers: Risk of disruption to relationships during the transaction.
• Creditors: Risk of credit ratings decline for the combined company following the proposed transaction.

Next Steps

• Completion of the proposed transaction between Waters, Augusta SpinCo Corporation, and Becton, Dickinson and Company, subject to closing conditions and regulatory approvals.
• Integration of SpinCo's businesses into Waters.
• Realization of anticipated benefits, including revenue and cost synergies.
• Continued execution of business strategy for the combined company.
• Transition from current Empower perpetual license model to a new subscription-based model for informatics.
• New organic bioseparations launches and bioanalytical characterization for LC-MS and MALS in PD and QA/QC.
• Expansion of PFAS opportunity into food & materials, and continued water testing growth.
• Leveraging GLP-1s triple-specced position across orals and injectables for lasting growth.
• Continued strong volume growth dynamics in India generics for export.

Key Dates

Recommendation

The filing outlines a highly strategic acquisition that is expected to significantly expand Waters' market presence, double its total addressable market to $40 billion, and generate substantial cost and revenue synergies. The company projects industry-leading financial performance for the combined entity, including superior revenue growth, EBIT margin expansion, and EPS growth compared to peers. This transformative transaction, coupled with Waters' demonstrated strong commercial execution and revitalized innovation, presents a compelling long-term growth opportunity for investors. While integration risks exist, the detailed synergy plans and positive outlook suggest a strong potential for shareholder value creation.

Keywords

Waters Corporation, Becton Dickinson, BD, Augusta SpinCo, Acquisition, Merger, Healthcare Conference, J.P. Morgan, SEC Filing, Form 8-K, Investor Presentation, Financial Outlook, Synergies, Life Sciences, Diagnostics, Chromatography, Mass Spectrometry, Flow Cytometry, Microbiology, Molecular Diagnostics, TAM, Revenue Growth, Operating Margin, EPS Growth